A multidisciplinary research team has discovered that liver alterations associated with metabolic dysfunction-associated fatty liver disease (MASLD) can directly cause cognitive and neurological impairments, and that these effects can be reversed by a therapy exclusively targeting the liver. The findings establish the existence of a “liver-brain axis” that is not only clinically relevant but also therapeutically actionable. The study demonstrates that animal models of diet-induced metabolic liver disease show alterations in social memory and sensory processing, accompanied by dysfunctions in the hippocampus, a key region for memory and learning. Most promisingly, these alterations were reversed by treating the liver with.